Compare
Electromed, Inc. vs Ceribell, Inc. vs Iridex Corp vs Outset Medical, Inc.
| Latest fiscal year | Electromed, Inc. ELMD | Ceribell, Inc. CBLL | Iridex Corp IRIX | Outset Medical, Inc. OM |
|---|---|---|---|---|
| Year ended | 2026-06-30 | 2025-12-31 | 2026-01-03 | 2025-12-31 |
| Revenue | $73.78M | $89.06M | $52.67M | $119.48M |
| Revenue growth (YoY) | +15.3% | +36.1% | +8.2% | +5.1% |
| Gross margin | 78.5% | 87.9% | 36.5% | 39.1% |
| Operating margin | 18.8% | -65.6% | -4.9% | -55.8% |
| Net margin | 15.3% | -60.0% | -8.4% | -68.3% |
| Net income | $11.30M | -$53.41M | -$4.44M | -$81.65M |
| EPS (Diluted) | $1.30 | -$1.46 | -$0.26 | -$5.37 |
| Operating cash flow | $9.66M | -$40.81M | -$2.12M | -$46.33M |
| Free cash flow | $8.41M | -$41.58M | -$2.26M | -$47.12M |
| Cash & equivalents | $20.45M | $40.48M | $6.03M | $35.01M |
| Total assets | $66.27M | $195.80M | $29.15M | $264.50M |
| Total liabilities | $12.29M | $40.47M | $24.23M | $137.54M |
| Shareholders' equity | $53.98M | $155.34M | $4.92M | $126.95M |
| Return on year-end equity | 20.9% | -34.4% | -90.1% | -64.3% |
| Shares outstanding | 8.37M | 37.49M | 17.31M | 18.17M |
Revenue, most recent five fiscal years
| Fiscal year | Electromed, Inc. | Ceribell, Inc. | Iridex Corp | Outset Medical, Inc. |
|---|---|---|---|---|
| Latest | $73.78M Ended 2026-06-30 | $89.06M Ended 2025-12-31 | $52.67M Ended 2026-01-03 | $119.48M Ended 2025-12-31 |
| 1 year earlier | $64.00M Ended 2025-06-30 | $65.44M Ended 2024-12-31 | $48.67M Ended 2024-12-28 | $113.69M Ended 2024-12-31 |
| 2 years earlier | $54.72M Ended 2024-06-30 | $45.23M Ended 2023-12-31 | $51.87M Ended 2023-12-30 | $130.38M Ended 2023-12-31 |
| 3 years earlier | $48.07M Ended 2023-06-30 | n/a | $56.97M Ended 2022-12-31 | $115.38M Ended 2022-12-31 |
| 4 years earlier | $41.66M Ended 2022-06-30 | n/a | $53.90M Ended 2022-01-01 | $102.60M Ended 2021-12-31 |